(Q72711248)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

title

Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

main subject

phase I clinical trial

1 reference

1 reference

K Itoh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

Y Sasaki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

Y Miyata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

H Fujii

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

T Ohtsu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

H Wakita

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

T Igarashi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

K Abe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

28 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

451-454

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00685653

28 October 2019

exact match

0 references

cites work

Choice of starting dose and escalation for phase I studies of antitumor agents

1 reference

12 December 2020

Therapeutic response in phase I trials of antineoplastic agents

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Responses and toxic deaths in phase I clinical trials

1 reference

12 December 2020

Potential roles for preclinical pharmacology in phase I clinical trials

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00685653

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7923553%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference